Ryan Nelson, PharmD

Specialties

• Precision medicine
• Somatic pharmacogenomics
• Germline pharmacogenomics
• Pharmacoeconomics

Education

• Doctorate Degree—Pharmacy, University of Utah College of Pharmacy
• Fellowship—Personalized Cancer Medicine, Moffitt Cancer Center

Memberships/Affiliations

• American Society of Hematology
• American Society of Health-System Pharmacists
• American Society of Human Genetics
• Clinical Pharmacogenetics Implementation Consortium

Research Interests

• Clinical utility and value of pharmacogenomics
• Gene-drug pair assessment for future implementation
• Patient adherence to pharmacotherapy

Recent Publications

• Nelson RS, et al. Prioritization of therapy options for a patient with high tumor mutation burden and microsatellite instability but no clinical benefit from immunotherapy. JCO Precis Oncol. 2019;3:PO.19.00197.
• Nelson RS, Hunter A, et al. CSF3R mutations are exceedingly rare genetic events associated with inferior survival and sensitivity to ruxolitinib across myeloid malignancies. Blood. 2019; 134 (Supplement_1): 4167.
• Stenehjem DD, et al. Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center. Melanoma Res. 2019;29(6):626–34.
• Wang Y, et al. Adherence to adjuvant imatinib therapy in patients with gastrointestinal stromal tumor in clinical practice: a cross-sectional study. Chemotherapy. 2019;64(4):197–204.
• Kim K, et al. Clinical utility of pharmacogenetic testing and a clinical decision support tool to enhance the identification of drug therapy problems through medication therapy management in polypharmacy patients. J Manag Care Spec Pharm. 2018;24(12):1250–9.
• Zhang M, et al. Prevalence and risk factors of immunosuppressant nonadherence in heart transplant recipients: a single-center cross-sectional study. Patient Prefer Adherence. 2019;13:2185–93.
• Au TH, et al. Impact of glioblastoma (GBM)-related cognitive dysfunction (CD) on caregiver burden: preliminary results from multi-site study in the U.S. Journal of Clinical Oncology. 2018;36(34_suppl):16.
• Au T, et al. HOUT-19. Development of a novel burden survey for caregivers of glioblastoma multiforme (GBM) patients. Neuro Oncol. 2017;19(Suppl 6):vi110.